Kickstart fat loss & regulate blood sugar
AOD-9604 is a specialized peptide fragment derived from human growth hormone; engineered to target fat reduction without influencing blood sugar or insulin levels. Also known as HGH Fragment 176-191, it stimulates the enzymatic breakdown of stored fat cells and inhibits the formation of new ones through a mechanism that is both selective and metabolically clean.
Administered as a subcutaneous injection five mornings per week on an empty stomach, AOD-9604 targets body fat reduction and metabolic health without the hormonal complexity of full growth hormone therapy.
The information provided on this page is for general informational purposes only and is not a substitute for professional medical advice. Always follow your RegenMD provider’s precise prescription and consult them directly with any questions or concerns. Not all patients qualify for every treatment—book a consultation to determine the best option for you.
AOD-9604 is administered as a subcutaneous (SubQ) injection, with a 30G/31G syringe at the prescribed dosage.
AOD-9604 was developed through the isolation of amino acids 176 through 191 from the C-terminus of the human growth hormone molecule; the specific region of HGH responsible for its fat-metabolizing effects. The full hGH molecule produces a range of biological activity including growth promotion, IGF-1 stimulation, and effects on blood sugar and insulin sensitivity. By working with only the 176-191 fragment, AOD-9604 retains the lipolytic activity of growth hormone while leaving the growth-promoting and metabolic side effects of the full molecule behind.
AOD-9604's primary mechanism is the activation of hormone-sensitive lipase (HSL); the enzyme within fat cells responsible for breaking stored triglycerides down into free fatty acids that the body can use as fuel. By binding to fat cell receptors and triggering HSL activation, AOD-9604 initiates lipolysis in a manner that mimics the way the body naturally mobilizes stored fat. This process is selective for adipose tissue rather than broad-spectrum metabolic stimulation, which is why AOD-9604 produces fat loss without the systemic effects of stimulants or appetite suppressants.
Simultaneously, AOD-9604 inhibits lipogenesis; the biochemical pathway by which the body converts dietary carbohydrates and other substrates into new fat cells. This dual action, stimulating the breakdown of existing fat while preventing the creation of new fat, addresses body composition from both directions at once. The insulin and blood sugar neutrality of the compound means it produces these effects without the metabolic trade-offs that limit the use of full growth hormone therapy in patients with insulin sensitivity concerns.
AOD-9604 also supports bone and cartilage health through mechanisms related to its activity in adipose-adjacent tissue, providing a secondary structural benefit alongside its primary fat metabolism function.
Administered as a subcutaneous injection five mornings per week on an empty stomach, AOD-9604 is most effective when the body is in a fasted state; insulin levels are low and the lipolytic environment is already primed. Your RegenMD provider establishes dosing based on your metabolic profile and monitors your response across the five or ten-week program.
Also find AOD-9604 in: Fat Burner
AOD-9604 is a synthetic peptide corresponding to amino acids 176-191 of the human growth hormone molecule; the fragment specifically responsible for HGH's fat-metabolizing activity. It was developed to isolate the lipolytic properties of growth hormone from its growth-promoting and blood sugar-affecting characteristics, producing a targeted fat loss compound with the metabolic selectivity that full hGH therapy lacks. At RegenMD, it is administered five mornings per week on an empty stomach as a standalone fat loss protocol or as a component of the Fat Burner Blend.
The growth-promoting and insulin-modulating properties of human growth hormone reside in a different region of the molecule from its fat-metabolizing activity. AOD-9604 corresponds only to the 176-191 fragment; the specific portion that activates hormone-sensitive lipase in fat cells to trigger lipolysis. Because it does not include the portions of hGH that stimulate IGF-1 or influence insulin signaling, it produces fat cell breakdown without the blood sugar and insulin effects that make full growth hormone therapy metabolically complex for some patients.
Full hGH therapy produces fat loss as one effect among many; it also stimulates bone and tissue growth, elevates IGF-1, and can affect insulin sensitivity. These additional effects require careful medical management and make hGH therapy inappropriate for many patients. AOD-9604 isolates the fat loss mechanism from the rest of hGH's biological activity, producing a compound that performs a specific metabolic function without the systemic hormonal complexity. Its safety profile was evaluated as part of its FDA drug development history, during which it received Generally Recognized as Safe status.
Lipolysis; the process AOD-9604 initiates; is most efficient when insulin levels are low. After an overnight fast, insulin is at its baseline and the body's fat oxidation pathways are already active. Administering AOD-9604 in this fasted state amplifies the lipolytic effect rather than working against the insulin activity that follows a meal. Eating before administration would elevate insulin, which suppresses lipolysis and reduces the compound's effectiveness at a mechanistic level.
GLP-1 therapy produces fat loss primarily through appetite suppression, slowed gastric emptying, and improved insulin sensitivity; it reduces caloric intake and improves metabolic efficiency. AOD-9604 works directly on fat cells; it does not reduce appetite or affect insulin and achieves fat loss by activating the enzymatic breakdown of existing fat stores and blocking the creation of new ones. GLP-1 addresses the input side of the fat accumulation equation; AOD-9604 addresses the stored fat itself. Patients whose primary barrier to fat loss is appetite and metabolic dysregulation may respond better to GLP-1; those seeking targeted fat cell reduction without appetite modification may find AOD-9604 better suited to their goals.
Your cart may be empty now, but let us help you fill it up with amazing products.